Arcutis Biotherapeutics Inc

10 de set. de 2026, 23:06 UTC

Arcutis Biotherapeutics shares are lower in after-market hours, continuing a downward trend observed over the past three sessions. The price remains below the 20-day moving average.

9 de set. de 2026, 19:26 UTC

Arcutis Biotherapeutics is declining amid broader market pressure from rising crude oil prices, which reached $100.49 per barrel during Wednesday's session.

8 de set. de 2026, 23:41 UTC

Arcutis Biotherapeutics shares rose in after-market trading, marking a shift from the recent trend of higher daily closes since Tuesday's close.

4 de set. de 2026, 20:07 UTC

Arcutis Biotherapeutics granted 57,000 RSUs to new employees, supporting growth initiatives. Shares are higher since Thursday's close despite a pullback earlier in the session.

1 de set. de 2026, 20:01 UTC

Arcutis Biotherapeutics Inc. shares are lower today, trading significantly below the 20-day moving average amid rising oil prices and inflation concerns.

31 de ago. de 2026, 19:36 UTC

Arcutis Biotherapeutics Inc shares are higher today, recovering from earlier losses despite no specific news to explain the price movement.

28 de ago. de 2026, 22:56 UTC

Arcutis Biotherapeutics shares are higher in after-market trading, though no specific news was identified. Broader market conditions may influence this movement.

26 de ago. de 2026, 20:08 UTC

Arcutis Biotherapeutics Inc shares are higher Wednesday, pulling back from session highs. Broader market fluctuations follow inflation data indicating rising consumer prices.

25 de ago. de 2026, 19:36 UTC

Arcutis Biotherapeutics shares are gaining as board member Terrie Curran exercised options for 1,072 shares valued at $18,642, according to an SEC filing.

24 de ago. de 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are trading lower, continuing a downward trend amid broader market dynamics and ahead of upcoming macroeconomic developments.

21 de ago. de 2026, 19:56 UTC

Arcutis Biotherapeutics Inc. is trading lower despite Health Canada's approval of PrZORYVE® cream for pediatric atopic dermatitis. The stock continues a downward trend since Thursday.

20 de ago. de 2026, 19:51 UTC

Arcutis Biotherapeutics Inc shares are lower despite Health Canada approving ZORYVE cream for pediatric atopic dermatitis, amid broader Biotechnology sector weakness.

19 de ago. de 2026, 19:26 UTC

Shares of Arcutis Biotherapeutics Inc. are higher today, maintaining an upward trajectory despite a modest pullback from an early high earlier in the session.

18 de ago. de 2026, 19:56 UTC

Arcutis Biotherapeutics Inc shares are higher today, following a notable peak earlier. The overall move remains positive since Monday's close amid rising Treasury yields.

14 de ago. de 2026, 20:06 UTC

Shares of Arcutis Biotherapeutics Inc. are advancing today, despite mixed market sentiment following a reported decline in U.S. retail sales for July.

13 de ago. de 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading lower with no specific news identified. The stock is below its 20-day moving average after recent gains.

12 de ago. de 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher amid positive market sentiment following a favorable inflation report, contributing to gains in major U.S. indices.

11 de ago. de 2026, 23:46 UTC

Arcutis Biotherapeutics shares are higher in after-market trading, reflecting broader market anticipation of modest inflation in the upcoming consumer price index report.

10 de ago. de 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading higher, rebounding from earlier lows. The stock remains below its 20-day moving average and near its one-month range.

7 de ago. de 2026, 23:31 UTC

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

6 de ago. de 2026, 22:16 UTC

Shares of Arcutis Biotherapeutics Inc. are trading higher in after-market hours, amid cautious investor sentiment following recent jobless claims data.

5 de ago. de 2026, 23:02 UTC

Arcutis Biotherapeutics reports Q2 net product revenues of $129.9 million and raises full-year sales guidance to $525 million to $540 million. Shares rise in after-market trading.

4 de ago. de 2026, 19:46 UTC

Arcutis Biotherapeutics is advancing during Tuesday's session amid a broader market boost from declining crude oil prices, easing inflation concerns.

3 de ago. de 2026, 21:01 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading, continuing a decline despite broader market gains and optimism over lower oil prices.

31 de jul. de 2026, 20:03 UTC

Arcutis Biotherapeutics Inc shares are lower today, continuing a decline since Thursday's close amid broader weak performance and no specific news identified.

30 de jul. de 2026, 23:51 UTC

Arcutis Biotherapeutics shares are lower in after-market trading, reflecting a broader decline since Thursday's close amid mixed Asian equity performance and geopolitical concerns.

29 de jul. de 2026, 19:19 UTC

Arcutis Biotherapeutics Inc. shares are lower as market sentiment reflects concerns over the Federal Reserve's upcoming monetary policy announcement amid inflationary pressures.

28 de jul. de 2026, 18:06 UTC

Arcutis Biotherapeutics Inc. shares are higher today, supported by a broader rally in biotechnology stocks, despite no specific company news identified.

27 de jul. de 2026, 16:07 UTC

Arcutis Biotherapeutics gained today after an Overweight rating from MS, which highlighted strong sales expectations for ZORYVE and cash flow break-even prospects.

24 de jul. de 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are lower today, reflecting routine performance within a narrow range amid no specific company news identified.